CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
CCTG clinical trials IND213, LY15 and MA31 have been permanently closed.
CCTG is launching the New-Investigator Cancer Trials Practicum to provide better engagement and training of new investigators with practical work in the field to allow for succession planning of top cancer trialists.
The Central Operations and Statistics Office is seeking nominations for the 2018 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. We are seeking nominations for the following Recognition Awards: Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research
The CCTG HN.9 study has been centrally activated in Canada, as of January 31.
HN.9 is a Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), 2018.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Lung Disease Site Committee Executive and the Quality of Life Committee.
